NASDAQ:RNXT

RenovoRx (RNXT) Stock Price, News & Analysis

RenovoRx logo
$0.95 -0.09 (-8.18%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.01 +0.05 (+5.46%)
As of 11/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About RenovoRx Stock (NASDAQ:RNXT)

Advanced

Key Stats

Today's Range
$0.90
▼
$1.06
50-Day Range
$0.95
▼
$2.20
52-Week Range
$0.73
▼
$2.59
Volume
824,478 shs
Average Volume
398,752 shs
Market Capitalization
$46.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Moderate Buy

Company Overview

RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body.

The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.

RenovoRx is based in Mountain View, California. Its clinical development program includes the TIGeR-PaC study, which is evaluating its treatment approach in pancreatic cancer.

AI Generated. May Contain Errors.

RenovoRx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

RNXT MarketRank™: 
2.389244729115 of 5 stars

RenovoRx scored higher than 48% of companies evaluated by MarketBeat, and ranked 566th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    RenovoRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    RenovoRx has a consensus price target of $8.50, representing about 790.1% upside from its current price of $0.95.

  • Amount of Analyst Coverage

    RenovoRx has only been the subject of 1 research reports in the past 90 days.

  • Read more about RenovoRx's stock forecast and price target.
  • Earnings Growth

    Earnings for RenovoRx are expected to grow in the coming year, from ($0.28) to ($0.20) per share.

  • Price to Book Value per Share Ratio

    RenovoRx has a P/B Ratio of 5.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.44% of the float of RenovoRx has been sold short.
  • Short Interest Ratio / Days to Cover

    RenovoRx has a short interest ratio ("days to cover") of 3.51, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in RenovoRx has recently increased by 15.43%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    RenovoRx does not currently pay a dividend.

  • Dividend Growth

    RenovoRx does not have a long track record of dividend growth.

  • News Sentiment

    RenovoRx has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for RenovoRx this week, compared to 4 articles on an average week.
  • Search Interest

    5 people have searched for RNXT on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added RenovoRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, RenovoRx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    9.40% of the stock of RenovoRx is held by insiders.

  • Percentage Held by Institutions

    3.10% of the stock of RenovoRx is held by institutions.

  • Read more about RenovoRx's insider trading history.
Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RNXT Stock News Headlines

Brokers Issue Forecasts for RenovoRx Q1 Earnings
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
HC Wainwright Issues Negative Outlook for RenovoRx Earnings
HC Wainwright Estimates RenovoRx's Q4 Earnings (NASDAQ:RNXT)
RenovoRx (NASDAQ:RNXT) Rating Lowered to "Sell" at Wall Street Zen
RenovoRx (RNXT) Q3 2026 Earnings Call Transcript
RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
See More Headlines

RNXT Stock Analysis - Frequently Asked Questions

RenovoRx's stock was trading at $0.8401 at the start of the year. Since then, RNXT stock has increased by 13.7% and is now trading at $0.9549.

RenovoRx, Inc. (NASDAQ:RNXT) released its quarterly earnings results on Thursday, November, 5th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The company had revenue of $1.07 million for the quarter, compared to analysts' expectations of $1.06 million. RenovoRx had a negative trailing twelve-month return on equity of 133.49% and a negative net margin of 469.02%.
Read the conference call transcript
.

RenovoRx (RNXT) raised $18 million in an initial public offering on Thursday, August 26th 2021. The company issued 1,800,000 shares at a price of $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

Top institutional investors of RenovoRx include AIGH Capital Management LLC (9.45%), State Street Corp (0.65%), T3 Companies LLC (0.21%) and Cetera Investment Advisers (0.12%). Insiders that own company stock include Ramtin Agah, Shaun Bagai, Mark Voll, Laurence Marton and Ron Kocak.
View institutional ownership trends
.

Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that RenovoRx investors own include Advanced Micro Devices (AMD), AST SpaceMobile (ASTS), SpaceX (SPCX), Archer Aviation (ACHR), Micron Technology (MU), NVIDIA (NVDA) and Ocugen (OCGN).

Company Calendar

Last Earnings
11/05/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:RNXT
CIK
1574094
Employees
17
Year Founded
2012

Price Target and Rating

High Price Target
$14.00
Low Price Target
$3.00
Potential Upside/Downside
+790.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.17 million
Net Margins
-469.02%
Pretax Margin
-469.02%
Return on Equity
-133.49%
Return on Assets
-101.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.65
Quick Ratio
5.53

Sales & Book Value

Annual Sales
$1.12 million
Price / Sales
41.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
5.03

Miscellaneous

Outstanding Shares
48,250,000
Free Float
43,715,000
Market Cap
$46.07 million
Optionable
Not Optionable
Beta
1.12

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:RNXT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners